Primary sclerosing cholangitis (PSC) is a chronic and rare liver disease characterized by progressive inflammation and scarring of the bile ducts within the liver. PSC causes bile duct injury which leads to bile-duct narrowing and bile build-up. If left untreated, it can lead to serious complications such as liver failure, cancer and ultimately liver transplant may be required. The disease often occurs in patients with ulcerative colitis, an inflammatory bowel disease. Medications help to treat the symptoms associated with PSC such as itching, infections of the bile ducts, abnormal blood tests, and fatigue.

The global Primary Sclerosing Cholangitis Market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030, as highlighted in a new report published by Coherent Market Insights.

Market Opportunity
An early diagnosis and treatment of PSC related symptoms provides a major market opportunity. Symptomatic medical therapies help alleviate disease burden and improve the quality of life for patients. Novel drug candidates targeting PSC pathogenesis are also being explored which will likely address the unmet need to slow disease progression. Development of safe and effective therapies for PSC represents a lucrative opportunity area for pharmaceutical companies to capitalize. Overall, the need to better manage PSC symptoms and disease course offers scope for sustained market growth over the forecast period.

Porter’s Analysis
Threat of new entrants: The primary sclerosing cholangitis market has moderate threat from new entrants due to high capital requirement for R&D of novel drugs and therapies.
Bargaining power of buyers: The bargaining power of buyers is low as treatment options are limited for primary sclerosing cholangitis.
Bargaining power of suppliers: Suppliers have moderate bargaining power due to presence of few established manufacturers with patented drugs and therapies.
Threat of new substitutes: Threat from new substitutes is low as there are limited treatment alternatives available for primary sclerosing cholangitis.
Competitive rivalry: The market witnesses high competitive rivalry due to presence of major companies focusing on development of novel therapies.

SWOT Analysis
Strength: Growing research on understanding disease pathology and development of novel treatment options. Rising awareness about early diagnosis and management.
Weakness: Lack of approved drugs for long term management. High cost of therapies limiting access.
Opportunity: Collaboration between industry and research institutes to develop effective drugs. Emerging role of biomarkers and diagnostic techniques.
Threats: Long approval timelines for new drugs. Risk of disease progression despite treatment.

Key Takeaways
The global Primary Sclerosing Cholangitis Market Demand is expected to witness high growth. The increasing research activities for developing novel treatment options and diagnosis are driving the market. The global primary sclerosing cholangitis market is estimated to be valued at US$ 1.98 Mn in 2023 and is expected to exhibit a CAGR of 7.6% over the forecast period 2023 to 2030.

Regional analysis: North America dominated the market and is expected to continue its dominance over the forecast period. Presence of established healthcare infrastructure and major market players in the region drive the market. Asia Pacific is anticipated to grow at fastest pace owing to rising patient pool, increasing healthcare expenditure and improving access to diagnosis and treatment.

Key players operating in the primary sclerosing cholangitis market are Acorda Therapeutics, Inc., Gilead Sciences, Inc., NGM Biopharmaceuticals, Inc., Intercept Pharmaceuticals, Inc., Dr. Falk Pharma GmbH, Allergan Plc., Shire Plc., Durect Corporation, Conatus Pharmaceuticals, Inc., Sirnaomics, Inc., and Shenzhen HighTide Biopharmaceutical Ltd. Key players are focusing on partnerships for development and commercialization of novel drugs for the condition.

Get more insights on this topic: https://www.pressreleasebulletin.com/primary-sclerosing-cholangitis-market-size-and-share/